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Infections with Plasmodium falciparum 
during pregnancy affect VAR2CSA DBL-5 
domain-specific T cell cytokine responses
Komi Gbédandé1,2,3 , Gilles Cottrell1,3,4, Bertin Vianou1, Samad Ibitokou1, Aurax Fernando1, 
Marita Troye‑Blomberg5, Ali Salanti6, Kabirou Moutairou2, Achille Massougbodji1, Nicaise Tuikue Ndam1,3,4, 
Philippe Deloron3,4, Adrian J. F. Luty3,4† and Nadine Fievet1,3,4*†
Abstract 
Background: Current knowledge of human immunological responses to pregnancy‑associated malaria‑specific 
Plasmodium falciparum protein VAR2CSA concerns almost exclusively B cell‑driven antibody‑mediated activity. 
Knowledge of VAR2CSA‑specific T cell‑mediated activity is minimal by comparison, with only a single published report 
of a study investigating VAR2CSA‑derived peptide‑specific T cell responses. The study described here represents an 
attempt to redress this balance.
Methods: Within the framework of a cohort study of 1037 pregnant Beninese, sub‑groups were selected on the 
basis of the documented presence/absence of infection with P. falciparum and conducted detailed immunological 
assessments both at inclusion into the study and at delivery. Peripheral blood mononuclear cells were isolated, stimu‑
lated in vitro, and VAR2CSA DBL‑5 domain‑specific, IFN‑γ‑secreting T‑cell frequencies and cytokine responses were 
quantified using flow cytometric techniques. Multivariate analyses were used to determine primarily whether the T 
cell‑mediated DBL5‑specific activity measured was associated with infection by P. falciparum adjusted for gravidity, 
anaemia and other cofactors.
Results: Infections with P. falciparum detected at inclusion were associated with enhanced non‑specific TNF 
responses, whilst diminished non‑specific and DBL‑5‑specific IL‑10 responses were associated with infections 
detected at delivery. Infections during pregnancy led to enhanced non‑specific and DBL‑5‑specific IFN‑γ responses 
detectable at delivery but to concomitantly lower DBL‑5‑specific CD8+ IFN‑γ responses. Prospective assessments 
indicated that non‑specific pro‑inflammatory responses detectable at inclusion in the study were associated with the 
occurrence of infections subsequently during pregnancy.
Conclusions: The findings represent a first step in elucidating the quantity and quality of cellular immunologi‑
cal responses to VAR2CSA, which will help in the development of the primary vaccine candidate for prevention of 
pregnancy‑associated malaria.
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Background
Pregnancy-associated malaria (PAM) due to infec-
tion with Plasmodium falciparum is a well-recognized, 
preventable cause of morbidity and mortality that 
impacts maternal, neonatal and infant health [1, 2]. Pre-
vention of PAM currently relies on the distribution of 
long-lasting insecticide-impregnated nets (LLINs) and 
use of the anti-malarial drug combination sulfadoxine-
pyrimethamine (SP) for intermittent preventive treat-
ment during pregnancy (IPTp). The World Health 
Organization (WHO) now recommends SP-IPTp given at 
Open Access
Malaria Journal
*Correspondence:  nadine.fievet@ird.fr 
†Adrian J. F. Luty and Nadine Fievet contributed equally to this work 
3 Institut de Recherche pour le Développement, MERIT UMR D216 Mère 
et enfant face aux infections tropicales, Paris, France
Full list of author information is available at the end of the article
Page 2 of 11Gbédandé et al. Malar J  (2016) 15:485 
least three times with monthly spacing during pregnancy, 
beginning in the second trimester. Both those existing 
tools suffer from significant insufficiencies in distribu-
tion and uptake as well as from the fact that resistance 
of Anopheles mosquitoes to insecticides and of P. falci-
parum parasites to SP, is now widespread across sub-
Saharan Africa [3]. A vaccine to prevent PAM would thus 
represent a valuable addition to the current set of tools 
available.
The study described here formed part of the EU FP7-
funded STOPPAM project (strategies to prevent preg-
nancy-associated malaria). STOPPAM aimed to generate 
the information necessary to accelerate the development 
of a vaccine to prevent PAM by conducting in-depth lon-
gitudinal studies of large numbers of pregnant women 
in Benin and Tanzania. Malaria infection may occur any 
time during the 9 months of pregnancy. The STOPPAM 
cohort enabled to demonstrate that early infection dur-
ing pregnancy is associated with higher risk of low birth 
weight and anemia at delivery [4, 5]. The results of those 
studies pointed strongly towards the existence of a natu-
rally acquired antibody-mediated form of immunity that 
rendered multigravidae women significantly less at risk of 
PAM than first-time mothers [6], with the consensus that 
the primary target of the antibodies induced is a parasite-
derived protein called VAR2CSA. Antibodies prevent 
the binding of infected erythrocytes, via the VAR2CSA 
expressed on their surface membranes, to their specific 
placental receptor, namely chondroitin sulphate A (CSA) 
expressed by syncytiotrophoblast [7, 8]. A wealth of 
information has been generated on multiple aspects of 
VAR2CSA-specific antibodies and the B cells responsible 
for their production [9–11]. Typically, VAR2CSA-spe-
cific IgG responses have been shown to display a strong 
gender- and gravidity-specific profile, pointing to the 
acquisition of protection against PAM during successive 
pregnancies [12–14]. Similar information on T cell-spe-
cific response to VAR2CSA is virtually non-existent.
The availability of such information could clearly be 
a valuable adjunct in the context of ongoing efforts to 
develop a vaccine to prevent PAM, since immunological 
memory requires the induction of antigen-specific T-cell 
cytokine-driven help for the efficient generation of B cells 
producing isotype-switched, affinity-matured, function-
ally active antibodies [15–17]. The VAR2CSA-DBL-5 
domain displays highly strain-transcendent epitopes sug-
gesting a role for additive or synergistic vaccine strategies 
that would combine both broad adhesion-blocking and 
opsonizing antibody responses to prevent high-density 
placental infections associated with disease [18].
The aim of the study described here was to investi-
gate the T-cell responses to the DBL-5 domain (in 2008 
it was considered one of the leading such candidates) 
in a cohort of pregnant women naturally exposed to 
malaria during their pregnancies. The authors’ hypoth-
esis was that infections occurring during pregnancy 
versus infections occurring only at delivery would have 
differential impacts on immune responses. Within the 
well-documented STOPPAM cohort, the study focused 
on two specific sub-groups in order to investigate: (i) cel-
lular immunological responses early in pregnancy as a 
predictor of P. falciparum infections during pregnancy; 
(ii) consequences of malaria and anaemia events dur-
ing pregnancy and at delivery on immune responses at 
delivery.
Methods
Study design
The STOPPAM project ‘strategies to prevent pregnancy 
associated malaria’ was conducted in Benin and Tanzania 
between November 2008 and April 2011. In Benin, the 
study took place in the district of Come, Mono Province, 
located 70  km west of the economic capital, Cotonou. 
Malaria transmission in the area has two peaks during 
the rainy seasons (from April to July, and from Septem-
ber to November). The entomological inoculation rate is 
35–60 infective bites per person per year [19]. The STOP-
PAM study design has been described in detail elsewhere 
[5]. Some 1037 women under 24 weeks of gestation were 
enrolled in three antenatal clinics: Come, Akodeha and 
Ouedeme Pedah. They were followed monthly with clini-
cal and parasitological surveillance up to and including 
delivery. According to national policy at the time of the 
study, pregnant women received IPTp with SP during 
their scheduled antenatal clinic visits (ANV). Women 
diagnosed with a clinical malaria attack (axillary temper-
ature  ≥37.5  °C with a positive malaria rapid diagnostic 
test (RDT) and/or a positive TBS) received a full treat-
ment course of quinine. In the case of clinical symptoms 
between ANV, mothers were encouraged to attend the 
maternity clinic to receive care.
For the study of CMI (cellular mediated immunity) to a 
recombinant protein corresponding to the DBL-5 domain 
of the PAM-associated parasite-derived VAR2CSA pro-
tein antigen in vitro described here, it was unrealistic to 
investigate all the women due primarily to cost consider-
ations. The study, therefore, worked only on sub-groups 
of 142 women at inclusion and 125 at delivery selected 
within the 1037 women (the target figure was 150 at each 
time point) (Fig. 1).
1. First at inclusion, women were selected harbouring P. 
falciparum infections and a similar number of moth-
ers with no infection.
2. At delivery, women were selected with the malaria 
history during pregnancy: (i) those who remained 
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uninfected throughout, (ii) those who had had at 
least one infection during pregnancy but who were 
not infected at delivery and (iii) a third group who 
were infected at delivery but who had varying histo-
ries of infection during pregnancy.
Only 22 women were represented in both the inclusion 
and delivery sub-groups.
Blood collection, peripheral blood mononuclear cell 
(PBMC) preparation
Peripheral venous blood samples (10 ml) were collected 
at different times (inclusion and/or delivery) in tubes 
containing citrate phosphate dextrose adenine (CPDA). 
All samples were transported within 4 h to the laboratory 
of the research centre for malaria during pregnancy and 
infancy (CERPAGE). PBMC were immediately isolated 
by density gradient centrifugation on Ficoll (Fisher Scien-
tific, UK) and freshly isolated cells were used for immu-
nological assays.
Plasmodium falciparum infection status
Clinical and parasitological data were collected from 
mothers at each ANV and also at delivery. Parasitologi-
cal status with respect to P. falciparum infection was 
determined using a RDT (Parascreen; Zephyr Biomedical 
Systems), as well as through routine microscopical exam-
ination of thick blood smears (TBS) and quantitative PCR 
(qPCR) on dried blood spots. Briefly, TBS were prepared, 
stained with Giemsa and examined by two experienced 
technicians for the presence and density of parasites. 
qPCR was performed after DNA extraction from blood 
spots dried on filter paper using the Chelex method, as 
described elsewhere [20]. At delivery, TBS were made 
from both peripheral and placental blood samples, such 
that maternal infection status at delivery was defined by 
the presence of parasites in either the placental and/or 
maternal peripheral blood.
Infection with P. falciparum was defined as a posi-
tive RDT and/or a positive TBS. Women with a positive 
PCR result but a negative blood smear and negative RDT 
result constituted a separate group identified as having 
sub-microscopic infections (SMI).
PBMC stimulation and cytokine quantification
3  ×  105 PBMC were cultured in 5  ml round-bottomed 
tubes (BD Biosciences) in 300  µl of complete medium 
(RPMI, 10  % FCS, 1  % l-glutamine, 50  µg/ml gentamy-
cin; Lonza) to which costimulatory receptors CD28/
CD49d (2  µl/ml, BD Biosciences, Grenoble, France) 
were added or were either left unstimulated or stimu-
lated either with mitogen (PHA 5 µg/ml, Sigma, France) 
or VAR2CSA DBL-5 antigen (5  µg/ml, a gift from Ali 
Salanti, was cloned into Baculovirus Centre for Medical 
Parasitology, University of Copenhagen), as described 
[21]. Cell cultures were incubated for 20 h at 37 °C in an 
atmosphere containing 5 % CO2. Cell-free culture super-
natants (150  µl) were collected after centrifugation of 
the tubes (at 450  g for 8  min) and subsequently stored 
in 50-µl aliquots at −80 °C prior to thawing for cytokine 
measurements.
IL-10, Il-13, IL-17, interferon gamma (IFN-γ), and TNF 
were quantified in culture supernatants using a commer-
cially available cytometric bead array (CBA soluble pro-
tein Flex set assay; BD Biosciences, Grenoble, France), 
conducted according to manufacturer’s instructions on 
a FACSCalibur 4-colour cytometer. The assay sensitiv-
ity was 0.13 pg/ml for IL-10, 0.6 pg/ml for IL-13, 0.3 pg/
ml for IL-17, 0.8  pg/ml for IFN-γ, and 1.2  pg/ml for 
TNF. When the cytokine concentration in a sample was 
below the detection limit of the test, an arbitrary value 
was assigned that corresponded to half of the sensitivity 
value for the specific cytokine concerned. Results were 
formatted using the BD CBA analysis software (FCAP 
array). The choice of these cytokines relies on their role 
in malaria immunity. The choice of these cytokines relies 
on their role in malaria immunity and the fact that the 
authors wished to target, as far as possible, cytokines 
produced exclusively or primarily by T cells. Placen-
tal malaria is associated with increased frequency of 
IFN-γ and TNF producing T lymphocytes suggesting an 
Fig. 1 Study design. Within the STOPPAM cohort, the study focused 
on two specific sub groups in order to investigate: (i) cellular immu‑
nological responses early in pregnancy as a predictor of P. falciparum 
infections during pregnancy; (ii) consequences of malaria and anae‑
mia events during pregnancy and at delivery on immune responses 
at delivery. At inclusion, 142 women were selected harbouring P. falci-
parum infections and a similar number of mothers with no infection. 
At delivery, 125 women were selected with the malaria history during 
pregnancy: (i) those who remained uninfected throughout, (ii) those 
who had had at least one infection during pregnancy but who were 
not infected at delivery and a third group (iii) who were infected at 
delivery but who had varying histories of infection during pregnancy
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important role of those cells and cytokines in protection 
[22]. The concentrations of the IL-10, TNF, and IFN-γ 
have been shown to be increased in placental or periph-
eral plasma in women with PAM [9, 23, 24].
Frequencies of IFN‑γ‑secreting T cells assessed by flow 
cytometry
1 × 106 PBMC were cultured in 1 ml of medium under 
the conditions described above except that, after 12  h 
of stimulation, secretion of proteins was inhibited by 
the addition of GolgiStop reagent (1  µl for 1  ml of cul-
ture medium). After 20  h’ incubation at 37  °C in 5  % 
CO2, cells were spin-washed with PBS-3 % FCS at 450 g 
for 8  min. IFN-γ intra-cellular staining was performed 
according to manufacturer’s recommendations (BD Bio-
sciences), all incubation steps being done in the dark. 
Briefly, 5  µl of FcR blocking reagent (Miltenyi Biotec, 
Cologne, Germany) were added to cells from each cul-
ture condition. After incubating the cells for 15  min at 
4 °C they were labelled by adding 5 µl of anti-CD8-FITC 
(BD Biosciences), and 5 µl of anti-CD4-PerCP (BD Bio-
sciences). Cells were lightly vortexed and incubated for a 
further 30 min at 4 °C. After spin-washing once at 450 g 
for 8 min with PBS-3 % FCS, the cells were resuspended 
in Perm-Wash Buffer (BD Biosciences) for 20 min at 4 °C. 
After again spin-washing with Perm-Wash Buffer, 3  µl 
anti-IFN-γ-PE (BD Biosciences) were added and cells 
incubated at 4  °C for 30  min. Finally, cells were spin-
washed again with Perm-Wash Buffer and acquired on 
the flow cytometer (BD FacsCalibur).
Statistical analysis
The associations between maternal characteristics or 
pregnancy outcomes and cytokine responses or frequen-
cies of T cell secreting IFN-γ, using univariate followed 
by multivariate linear regression, using robust variance 
estimation were investigated. The analyses were thus per-
formed in two steps: first a univariate model which aimed 
to identify potential confounders and the crude asso-
ciations between cytokine responses and the pregnancy 
outcomes using the non-parametric Kruskal–Wallis and 
Mann–Whitney tests. In a second step, association lead-
ing to a p value less than 0.2 were selected for the fol-
lowing multivariate model. The baseline characteristics 
subsequently selected for inclusion in the multivariate 
analyses were gravidity, maternal anemia (Hb < 11 g/dl), 
premature birth (<37 weeks) and P. falciparum infection 
(microscopic and sub-microscopic).
Following the hypothesis, the profile of DBL-5-specific 
cellular immunological responses observed at delivery 
should reflect exposure to P. falciparum infection during 
pregnancy, but that the presence of infection at delivery 
could alter or mask such profiles. The detailed infection 
histories that were collected from STOPPAM mothers 
via the close surveillance conducted between inclusion 
into the study and delivery benefit to better elucidate 
these issues. Those histories allowed to split the deliv-
ery sub-group in three groups of women: (i) those who 
remained uninfected throughout; (ii) those who had had 
at least one infection during pregnancy but who were not 
infected at delivery; and a third group, and (iii) who were 
infected at delivery but had varying histories of infection 
during pregnancy.
Statistical significance in all multivariate analyses was 
considered if p values were <0.05. All analyses were per-
formed using the Stata/MP 12.0 (StataCorp, College Sta-
tion, TX, USA) and graphs were made with GraphPad 
(Prism 6.0).
Results
Characteristics of the study population
Table  1 gives an overview of the sub-groups’ character-
istics. In terms of their gravidity, their age distribution, 
as well as of the proportions of low birth weight (LBW) 
babies and of anaemic mothers, the sub-groups displayed 
broadly similar profiles. Since the presence of infection 
with P. falciparum was a criterion for entry into the sub-
groups both at inclusion and at delivery, it is according 
to expectation that those parameters differ markedly 
between the sub-groups. In the sub-group selected at 
inclusion, 50 % were infected according to the results of 
examination of TBS whilst 19 % of the same individuals 
were found to be infected at delivery. In the sub-group 
Table 1 Study population characteristics
a 22 women overlap at inclusion and at delivery
Inclusion sub‑
group (n = 142)a
Delivery 
sub‑group 
(n = 125)a
Primigravid 38 23
Secundi‑/multi‑gravid 104 102
Age, mean (SD) in years 25 (6) 26 (6)
Gravidity score, mean (SD) 2.9 (1.9) 3.2 (1.9)
% Low birth weight (LBW: <2500 g) 13 15
% Anemic (Hb < 11 g/dl)
 At inclusion 70 60
 At delivery 42 41
At inclusion
 P. falciparum infected, n (%)
  Microscopy 71 (50) 25 (14)
  PCR 19 (13) 34 (25)
At delivery
 P. falciparum infected, n (%)
  Microscopy 20 (19) 37 (30)
  PCR 36 (20) 37 (30)
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selected at delivery, 30 % were infected according to TBS 
whilst 14  % of the same individuals were found to be 
infected at inclusion. PCR-based detection consistently 
augmented the proportions found to be infected regard-
less of the sub-group or the time-point concerned. For 
reference purposes, one can note that in the whole STOP-
PAM cohort infections were detected by microscopy (of 
TBS) and PCR in, respectively, 16 and 40  % mothers at 
inclusion, compared with 11 and 34 % at delivery [4]. All 
microscope-positive TBS were also PCR positive.
Cytokine responses of PBMC at inclusion and at delivery
PBMC from the two different sub-groups of pregnant 
women at inclusion and at delivery were stimulated with 
mitogen (PHA) or with the recombinant protein DBL-5. 
The cytokines IL-10, IL-13, IL-17, IFN-γ, and TNF were 
quantified in culture supernatants. All data are pre-
sented after subtraction of cytokine concentrations in 
the supernatants of unstimulated PBMC from those in 
supernatants of stimulated cells (Table 2). Notably, IL-17 
was present at low levels after mitogen stimulation but 
was undetectable in unstimulated and DBL-5-stimulated 
samples. The other cytokines quantified were present, as 
expected, at appreciable levels following mitogen stimu-
lation, whilst DBL-5 stimulated appreciable production 
of both IL-10 and TNF, but comparatively little IFN-γ or 
IL-13. Regardless of the mitogen stimulation, the concen-
trations of IFN-γ, IL-10, IL-13 and TNF and only for TNF 
after DBL-5 stimulation were consistently lower in super-
natants of cultures of PBMC taken at delivery compared 
to those of PBMC taken at inclusion (Table 2; see Addi-
tional file 1). A similar pattern was evident with respect 
to the frequencies of T cells secreting IFN-γ as detected 
by intracellular staining (Table  3). Thus, regardless of 
cell type (CD4+ or CD8+) the frequencies of T cells pro-
ducing IFN-γ following mitogen stimulation of PBMC 
at delivery were significantly lower than the frequencies 
observed at inclusion (univariate analysis p  =  0.0013, 
p = 0.0002 respectively), whilst the frequencies detected 
following stimulation with the parasite-specific DBL-5 
protein were similar at the two time-points (Table 3).
The influence of maternal anaemia and gravidity on the 
cytokine responses of PBMC at inclusion and delivery
Multivariate analyses showed anaemia at delivery to be 
associated with a significantly higher TNF response to 
PHA (p = 0.01) at delivery, but no other associations were 
evident. Univariate analyses (Fig. 2), comparing PBMC at 
delivery of primigravidae with those of secundi-/multi-
gravidae women (≥two pregnancies), revealed higher 
frequencies of DBL-5-specific IFN-γ-producing CD4+ 
and CD8+ T-cells (p = 0.06 and p = 0.019, respectively) 
in multigravid compared to primigravid women at deliv-
ery. Multivariate analyses controlling for maternal anae-
mia, premature birth and P. falciparum infection did not 
reveal significant associations with gravidity.
The influence of current P. falciparum infections either at 
inclusion or at delivery on cytokine responses of PBMC 
on both inclusion and delivery sub‑groups respectively
Since there was no a priori knowledge of the possible 
effects of sub-microscopic P. falciparum infections (those 
identified solely by PCR) on the cellular immunological 
parameters were assessed, it was important to first deter-
mine whether the differences seen in those parameters 
were detectable as a function of the presence of such 
infections or not [4]. In univariate analyses comparing 
either cytokine concentrations in supernatants or the 
frequencies of IFN-γ-producing T-cells, for both stimu-
lus (PHA/DBL-5) and at either time-point, there were 
no discernible differences or marked trends that distin-
guished the groups with sub-microscopic infections from 
those either with microscopic or with no infections (data 
not shown). Nevertheless, for subsequent multivariate 
analyses those identified solely by PCR as being infected, 
i.e., truly sub-microscopic infections were considered 
separately as a group (SMI) for comparison of their 
Table 2 Cytokine concentrations in culture supernatants following in vitro stimulation of PBMC
Values are median concentrations (IQR) in pg/ml
a Numbers are reduced due to insufficient quantities of PBMC to perform all assays
b Cytokine concentration significantly lower than corresponding concentration in supernatants of PBMC at inclusion (p < 0.05 in all cases)
IL‑10 IFN‑γ TNF IL‑13
Inclusion (n = 130)a
 PHA 643 (216–1291) 4807 (1759–9021) 8567 (5081–14,620) 684 (291–1205)
 DBL‑5 341 (0.06–847) 0.4 (0.4–259) 3710 (1643–6872) 0.3 (0.3–13)
Delivery (n = 109)a
 PHA 233 (0.06–1261)b 1303 (332–4326)b 6279 (3404–9470)b 364 (65–757)b
 DBL‑5 195 (0.06–712) 0.4 (0.4–0.4) 2568 (1521–4981)b 0.3 (0.3–0.3)
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cytokine responses with those of the microscopically 
infected (MI) and the uninfected (UI) groups of women.
Univariate analyses of data from the inclusion sub-
group revealed a significantly increased amount of mito-
gen-induced TNF from PBMC of the MI compared with 
the UI group, but this was the only difference observed 
between the groups UI versus MI versus SMI. For the 
delivery sub-group, infection at delivery was associated 
with a significantly diminished level of IL-10 in response 
to both PHA and DBL-5, as well as a significantly reduced 
frequency of DBL5-specific IFN-γ-producing CD4+ T 
cells in MI versus UI. Multivariate analyses controlling 
for relevant confounders confirmed those observations 
concerning the differing profiles of production of TNF 
at inclusion and of IL-10 at delivery in PBMC of the MI 
group.
The influence of Plasmodium falciparum infections 
during pregnancy and/or at delivery on cytokine 
responses of PBMC from the delivery sub‑group
The profile of DBL-5-specific cellular immunological 
responses observed at delivery was predicted to reflect 
exposure to P. falciparum infection during pregnancy, 
but the presence of infection at delivery could alter or 
mask such profiles. In order to better elucidate these 
issues use was made of the detailed infection histories 
that were collected from STOPPAM mothers via the 
close surveillance conducted between inclusion into the 
study and delivery. Those histories allowed identification 
of three groups of women described in the methods, (i) 
those who remained uninfected throughout, (ii) those 
who had had at least one infection during pregnancy but 
who were not infected at delivery and a third group (iii) 
who were infected at delivery but who had varying his-
tories of infection during pregnancy. Figure 3 illustrates 
the cytokine responses of these three groups reflecting 
exposure or not to P. falciparum infection during preg-
nancy, revealing that infection at delivery is associated 
with a reduction in IL-10 responses both to mitogen 
and to DBL-5. Multivariate analyses showed that PBMC 
at delivery of mothers with a history of infection during 
pregnancy but who were uninfected at delivery displayed 
significantly increased production of IFN-γ in response 
to both PHA and DBL-5 stimulation (p  =  0.003 and 
p  =  0.037, respectively) as well as increased PHA-spe-
cific IL-13 (p = 0.001) compared to PBMC of uninfected 
women (Fig. 4).
Separately, the relationships between the cumu-
lated number of P. falciparum infections during preg-
nancy and the cytokine profile displayed by PBMC 
Table 3 The frequencies of  IFN- γ -secreting cells follow-
ing in vitro stimulation of PBMC
Values are median frequencies (IQR)
a Numbers are reduced due to insufficient quantities of PBMC to perform all 
assays
b Frequencies significantly lower than corresponding frequencies at inclusion 
(p < 0.001 in both cases)
% IFN‑γ secreting 
CD4+ T cells
% IFN‑γ secreting CD8+ 
T cells
Inclusion (n = 92)a
 PHA 6.95 (4.65–9.74) 6.37 (4.02–8.59)
 DBL‑5 1.44 (0.49–2.32) 1.71 (0.67–2.46)
Delivery (n = 61)a
 PHA 4.28 (2.85–7.08)b 3.34 (2.01–5.49)b
 DBL‑5 1.47 (0.65–2.02) 1.49 (0.98–2.27)
Fig. 2 Cytokine responses in PBMC after specific and non‑specific stimulation at delivery according to gravidity. IFN‑γ‑secreting T cells frequencies 
in response to PHA and to recombinant protein DBL‑5 compared primigravidae women with multigravidae women (≥two pregnancies). All box 
plots illustrate medians with 25th and 75th percentiles and whiskers for 10th and 90th percentiles. p values were determined by the non‑parametric 
Mann–Whitney U test in an univariate analysis and significant differences are depicted by p < 0.05
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at delivery were also examined, segregating women 
into three groups: (i) uninfected during pregnancy, 
(ii) one P. falciparum infection during pregnancy, and 
(iii) two or more P. falciparum infections during preg-
nancy, excluding those with infections at delivery from 
these analyses. Multivariate analyses that adjusted for 
potential confounders (anaemia, gravidity, premature 
birth), revealed significantly higher levels of IFN-γ 
(p = 0.004) and IL-13 (p = 0.019) in response to PHA 
and a significantly higher level of IFN-γ (p  =  0.04) 
in response to DBL-5 of PBMC from mothers more 
often infected during pregnancy compared to unin-
fected mothers (data not shown). These analyses also 
revealed a lower frequency of DBL-5-specific IFN-
γ-secreting CD8+ T cells (p =  0.022) as a function of 
increasing numbers of P. falciparum infections during 
pregnancy.
Cellular immunological responses at inclusion as a 
predictor of Plasmodium falciparum infections 
during pregnancy
Whether the cytokine responses or frequencies of IFN-
γ-secreting T cells upon in vitro stimulation at inclusion 
were predictive of P. falciparum infections during preg-
nancy were determined. Multivariate analysis revealed 
independent associations for an increased risk of P. 
Fig. 3 Cytokine responses in PBMC at delivery according to malaria histories during pregnancy. The frequencies of IFN‑γ‑secreting T cells and 
cytokine production in PBMC at delivery in response to PHA and to recombinant protein DBL‑5 are shown. The three groups of women were 
defined based on their exposure to P. falciparum infection during pregnancy: (i) those who remained uninfected throughout (white box plot), (ii) 
those who had had at least one infection during pregnancy but who were not infected at delivery (grey box plot), and (iii) who were infected at 
delivery but who had varying histories of infection during pregnancy (black‑hatched box plot). Except for IFN‑γ and IL‑13 production in response to 
DBL‑5, all box plots illustrate medians with 25th and 75th percentiles and whiskers for 10th and 90th percentiles. The box plots for IFN‑γ and IL‑13 
production in response to DBL‑5 show the mean with SEM (standard error of the mean). The statistical significance of differences between groups 
was determined using the non‑parametric Kruskall Wallis test, p < 0.05
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falciparum infection during pregnancy with (i) higher 
TNF, and (ii) a higher frequency of IFN-γ secreting CD8+ 
T cells, both in response to PHA (p =  0.04, p =  0.051, 
respectively), at enrolment.
Discussion
This study was designed to generate information to allow 
both prospective and retrospective analyses of the inter-
actions between cellular immunological responses and 
infections with P. falciparum during pregnancy. The pro-
spective analyses revealed two main findings concern-
ing, on the one hand, non-specific CD8+ T-cell IFN-γ 
responses, and on the other, non-specific TNF responses. 
In the first case, women more likely to be re-infected 
during pregnancy were those in whom an elevated 
non-specific CD8+ T-cell IFN-γ response was detect-
able at inclusion. Notably here is the fact that, in retro-
spective analyses, antigen-specific CD8+ T-cell IFN-γ 
responses declined as a function of increasing numbers 
of re-infections. These findings could point to CD8+ T 
cell IFN-γ responses as being detrimental in the context 
of protection from P. falciparum infections during preg-
nancy. These observations in this context are novel and 
merit further investigation. Asexual blood stage parasite-
antigen specific CD8+ T-cell responses are a documented 
feature of controlled human malaria infections in adults 
[25]. The function, if any, of such cells remains a para-
dox given that their potential targets, erythrocytes, do 
not express HLA Class I molecules. Based on studies in a 
mouse malaria model it is conjectured that they may have 
a ‘bystander’ role concerning activation of phagocytic 
activity [26].
The second finding from prospective analyses con-
cerned elevated non-specific TNF responses at inclusion 
that were a prognostic marker for subsequent infections. 
This observation is clearly incompatible with the pur-
ported protective role against infection detected at deliv-
ery attributed to non-specific proinflammatory responses 
Fig. 4 Cytokine responses of PBMC at delivery according to P. falciparum infections during pregnancy. The frequencies of IFN‑γ secreting CD4+ and 
CD8+ T cells and cytokine production in PBMC at delivery in response to PHA or to the recombinant protein DBL‑5 are shown. Excluding malaria 
infections at delivery and according to malaria infection during pregnancy, two groups were defined with uninfected women (white) and infected 
women (black). Excepted for IFN‑γ and IL‑13 production in response to DBL‑5, all box plots illustrate medians with 25th and 75th percentiles and 
whiskers for 10th and 90th percentiles. The box plots for IFN‑γ and IL‑13 production in response to DBL‑5 indicate the mean with SEM (standard error 
of the mean). The statistical significance was determined using multivariate analysis model, p < 0.05
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measured at recruitment in a cohort of Papua New Guin-
ean women [27]. Whether or not, in the context of the 
latter study, (i) the timing of recruitment and/or (ii) life-
long exposure to both P. vivax and P. falciparum have any 
bearing on this issue remain open questions. The pro-
spective analyses in that study, it should nevertheless be 
noted, did also show that lower non-specific Treg-IL-10 
(anti-inflammatory) levels were associated with future P. 
falciparum infections. Taken on its own, that observation 
is not incompatible with a higher non-specific proinflam-
matory (e.g. TNF) response being associated with future 
infection, as was observed here. In all this, it seems to us 
clear that the issue of the quality of the cellular immuno-
logical response involved is likely to have as much impor-
tance as its quantity. Thus, a proinflammatory response 
generated via an antigen-specific interaction that is 
guided predominantly by IFN-γ will almost certainly dif-
fer in quality from a proinflammatory response generated 
via a non-specific route that is guided predominantly by 
TNF. It is perhaps also instructive to note that in our own 
and others’ studies the peripheral plasma levels of neither 
IFN-γ nor TNF vary as a function of the presence of P. 
falciparum infections during pregnancy but that their 
placental plasma levels—measured at delivery—certainly 
do [28–30]. For obvious reasons the placental compart-
ment, other than at delivery, remains uncharted territory 
for the sorts of studies that could help to answer some of 
the outstanding immunological questions in the context 
of an infection during pregnancy that is localised to the 
placenta itself. This is, then, the major limitation of the 
study presented here, since assessments of the respon-
siveness of circulating T cells may represent only an 
approximation of events localised to and focused on the 
placental space.
In retrospective analyses, the aim was to assess the 
impact of P. falciparum infections documented dur-
ing pregnancy on the cellular immunological responses 
measured at delivery. The findings in this regard point 
clearly to the generation of an IFN-γ-led antigen-specific 
T-cell memory response, measurable in peripheral blood 
samples at delivery, a type of response that is, as the data 
further show, augmented by re-infections during preg-
nancy in a manner that does not reflect the gravidity. As 
mentioned above, a concomitantly reduced antigen-spe-
cific CD8+ T-cell IFN-γ response at delivery as a function 
of increasing numbers of infections during pregnancy 
was observed. A previously published study documented 
a significant gestational age-related decline in the over-
all frequency, ex vivo, of CD4+ T cells between the sec-
ond trimester and delivery, accompanied by increased 
frequencies of CD8+ T cells [31]. Those profiles con-
trast clearly with the in vitro stimulation-derived profiles 
reported here. The latter suggest that pathogen antigen-
specific responsiveness is maintained despite pregnancy-
related alterations in lymphocyte populations.
Infection at the time of blood draw modified the cel-
lular immunological responses detectable, and the nature 
of those modifications, furthermore, reflected the time-
point (inclusion versus delivery). The authors noted ele-
vated non-specific TNF at inclusion versus diminished 
specific/non-specific IL-10 at delivery. These findings 
are consistent with earlier observations showing altered 
ex vivo peripheral blood cell profiles on the one hand [32] 
and altered cytokine levels—primarily increased IL-10—
on the other [31], as being associated with infection in 
these women. It is notable here that infection per se tends 
to generate T-cell-mediated cellular responses, whether 
specific or non-specific, that favour inflammation. In the 
context of a successful pregnancy, inflammatory activ-
ity needs to be counter-balanced by anti-inflammatory 
activity [33] which likely explains the elevated circulating 
plasma IL-10 levels consistently associated with P. falci-
parum infections during pregnancy. In the context of the 
latter, the data presented here suggest that the primary 
source of infection-related IL-10 is probably not T cells. 
Placental cells are the most likely source given that the 
infections are localized there.
Other than the impossibility of accessing the placental 
compartment during pregnancy, the study’s shortcom-
ings are primarily related to sub-group sizes that were 
necessarily limited both by resources and by cell numbers 
(blood volumes) available. A separate issue concerns the 
limited number of stimuli used, also again a reflection of 
resources available.
Conclusions
The findings presented here represent a first step in doc-
umenting cellular immunological responses to the can-
didate vaccine antigen VAR2CSA and, in particular, how 
infection with P. falciparum during pregnancy modulates 
such responses. As such these observations contribute 
important information to the design of future evaluations 
in the specific context of VAR2CSA-based vaccine trials.
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stimulation of PBMC at inclusion and at delivery. The frequencies of IFN‑γ‑
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and IL‑13 production in response to DBL‑5, all box plots illustrate medians 
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the mean with SEM (standard error of the mean). The univariate statistical 
significance of differences between groups was determined using the 
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